Mounjaro 12.5mg KwikPen contains Tirzepatide, a dual GIP and GLP-1 receptor agonist used for type 2 diabetes management. It is taken once a week and helps with weight loss and blood sugar control.

Brand Name: Mounjaro

Composition: Tirzepatide

Mechanism of Action:

A dual GIP and GLP-1 receptor agonist, tirzepatide aids in controlling blood sugar levels in people with type 2 diabetes. It functions by slowing stomach emptying, which raises satiety and may aid in weight loss, decreasing glucagon levels to lower blood sugar, and increasing insulin production in response to meal consumption.

Uses:

·       Type-2 Diabetes Mellitus

·       Weight Management

Dosage and Administration:

·       The recommended dosage is 12.5 mg once weekly subcutaneously (abdomen, thigh, or upper arm, rotating sites).

·       After taking 10 mg once weekly for at least four weeks, this dosage is used.

·       The dosage may be raised to a maximum of 15 mg once weekly if more glycemic control is needed.

·       It can be taken with or without food, at any time of day; if a dose is missed, it should be taken within four days; otherwise, skip the dose and carry on as usual.

Side Effects:

·       Nausea

·       Vomiting

·       Diarrhea

·       Constipation

·       Decreased appetite

·       Injection site reactions (Itching, Rashes)

·       Hypoglycemia

Safety Advise:

Lungs  

The safety of Mounjaro for individuals with lung issues is uncertain. Kindly speak with your healthcare provider.

Liver  

The safety of Mounjaro for individuals with liver issues is uncertain. Kindly speak with your healthcare provider.

Kidney  

The safety of Mounjaro for individuals with Kidney issues is uncertain. Kindly speak with your healthcare provider.

Pregnancy  

Mounjaro should be used during pregnancy only if clearly needed, Kindly speak with your healthcare provider.

Breast Feeding  

Using Mounjaro while nursing is most likely dangerous. Kindly speak with your healthcare provider. 

Storage:

Avoid freezing the Mounjaro KwikPen and keep it in a refrigerator between 2°C and 8°C. After usage, it can be stored for 21 days at room temperature (up to 30°C) under protection from heat and light.

How to use this Medication?

This drug is administered subcutaneously. You'll learn how to prepare and administer it. It is administered once every seven days, or once a week. Unless instructed otherwise by your healthcare provider, continue taking it.

You should inject this medication and insulin separately if you take both together. Don't combine them. Avoid administering the shots directly close to one another. With every injection, rotate the injection sites.

References:

1.   Baker DE, Walley K, Levien TL. Tirzepatide. Hospital Pharmacy. 2023 Jun;58(3):227-43.

2.  Karagiannis T, Avgerinos I, Liakos A, Del Prato S, Matthews DR, Tsapas A, Bekiari E. Management of type 2 diabetes with the dual GIP/GLP-1 receptor agonist tirzepatide: a systematic review and meta-analysis. Diabetologia. 2022 Aug;65(8):1251-61.

3.  Jastreboff AM, Aronne LJ, Ahmad NN, Wharton S, Connery L, Alves B, Kiyosue A, Zhang S, Liu B, Bunck MC, Stefanski A. Tirzepatide once weekly for the treatment of obesity. New England Journal of Medicine. 2022 Jul 21;387(3):205-16.

4.  Chavda VP, Ajabiya J, Teli D, Bojarska J, Apostolopoulos V. Tirzepatide, a new era of dual-targeted treatment for diabetes and obesity: a mini-review. Molecules. 2022 Jul 5;27(13):4315.

Disclaimer:

The main goal of Apothecare Wellness is to make sure that the information it provides to customers is correct, reliable, and reviewed by specialists. This website's contents and information are strictly for informational purposes. They are not meant to be used in place of expert medical advice, diagnosis, or care. Please consult your physician for guidance and ask any questions you may have about any condition or medication. If you read anything on Apothecare Wellness, do not discount or delay obtaining competent medical advice. Our goal is to enhance the doctor-patient relationship, not to take its place.

Marketer details

Name: Eli Lilly and Company India Pvt Ltd

Address: Plot# 92, Sector 32, Institutional Area, Gurgaon-122001, HARYANA, INDIA

Country of origin: United states